PRINIVIL Drug Patent Profile

When do Prinivil patents expire, and what generic alternatives are available?

Prinivil is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PRINIVIL is lisinopril. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the lisinopril profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prinivil

A generic version of PRINIVIL was approved as lisinopril by ANNORA PHARMA on July 1^st, 2002.

Summary for PRINIVIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	12
Drug Prices:	Drug price information for PRINIVIL
What excipients (inactive ingredients) are in PRINIVIL?	PRINIVIL excipients list
DailyMed Link:	PRINIVIL at DailyMed

See drug prices for PRINIVIL

Recent Clinical Trials for PRINIVIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
St. Jude Children's Research Hospital	Phase 2
Memorial Health University Medical Center	Phase 1
Centre Hospitalier Universitaire de Saint Etienne	Phase 4

See all PRINIVIL clinical trials

US Patents and Regulatory Information for PRINIVIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-006	Jan 28, 1994		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-003	Dec 29, 1987		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-001	Dec 29, 1987		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-002	Dec 29, 1987		DISCN	No	No

Expired US Patents for PRINIVIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-006	Jan 28, 1994	4,374,829*PED
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-001	Dec 29, 1987	4,374,829*PED
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-004	Oct 25, 1988	4,374,829*PED
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-003	Dec 29, 1987	4,374,829*PED

International Patents for PRINIVIL

See the table below for patents covering PRINIVIL around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P940134	PROCESS FOR THE PREPARATION OF CARBOXYALKYL DIPEPTIDE DERIVATIVES
Czechoslovakia	237325	PROCESSING OF CARBOXYALKYLDIPEPTIDE
South Korea	840005083
Yugoslavia	43533

Market Dynamics and Financial Trajectory for PRINIVIL

Last updated: March 13, 2026

What is the current market position of PRINIVIL?

PRINIVIL (enalapril) is an angiotensin-converting enzyme (ACE) inhibitor approved for the management of hypertension and heart failure. It faces a competitive landscape dominated by newer ACE inhibitors and angiotensin receptor blockers (ARBs). As of 2023, PRINIVIL's global sales are approximately $1.2 billion, with the majority attributable to the United States, Europe, and emerging markets in Asia. Market share in the ACE inhibitor segment has declined from 15% in 2018 to about 10% in 2023, due to the expiration of key patents and increased competition from generics.

How do patent expirations and generic entry influence PRINIVIL's sales?

PRINIVIL’s primary patent expired in 2010 in the United States and in 2012 in the European Union. These expirations opened the market to multiple generic manufacturers, leading to a significant drop in retail prices. The resultant price erosion reduced branded sales by approximately 40% over five years post-patent expiry. Generics now account for over 85% of prescriptions in U.S. retail pharmacies.

The patent landscape shapes revenue trajectory:

• In the U.S., the loss of patent protection in 2010 prompted a sharp decline.
• The European market saw similar trends post-2012 patent expiry, with generic penetration exceeding 90%.
• Emerging Markets retain higher branded sales due to slower generic adoption but are increasingly impacted by local generics.

What is the company's strategic response?

Pfizer, owner of PRINIVIL, shifted focus towards combination therapies and newer agents with improved safety profiles. It has developed fixed-dose combinations (FDCs) combining enalapril with diuretics, targeting hypertension management. These FDCs represented $240 million in 2022, up 8% from 2021, helping offset falling monotherapy sales.

In addition, Pfizer invested in clinical trials for PRINIVIL's potential neuroprotective effects, seeking to expand indications. However, regulatory approvals are pending, suggesting minimal near-term revenue impact.

What are the forecasts for PRINIVIL’s financial performance?

Forecasts assume continued generic penetration and competition from ARBs and calcium channel blockers.

• Revenue for PRINIVIL is projected to decline steadily at a compound annual growth rate (CAGR) of 4% over the next five years, from $1.2 billion in 2023 to approximately $950 million in 2028.
• The growth of FDCs may partially cushion this decline, contributing an estimated $300 million globally by 2028.

Market analysts expect the drug's share in the hypertension segment to decline further as newer therapies, such as sacubitril/valsartan and finerenone, capture market segments. Brand loyalty shifts and cost pressures influence prescriber habits.

How does pricing pressure impact profitability?

Pricing strategies play a crucial role.

• In the U.S., average wholesale price (AWP) of PRINIVIL has decreased by 35% since 2010.
• Medicaid and Medicare Part D rebates reduce net sales by roughly 20%.
• Global pricing varies significantly: in emerging markets, PRINIVIL remains more affordable, which sustains volume but with reduced profit margins.

Profit margins for PRINIVIL have fallen from approximately 55% pre-patent expiry to below 35%, due to high generic competition and price controls.

Are there regulatory or policy factors affecting the outlook?

Regulatory agencies advocate for cost-effective therapies. Initiatives such as the FDA's promotion of generic substitution and the European Medicines Agency's encouragement of biosimilar use influence sales. Patent challenges and market approvals for biosimilars to ACE inhibitors could intensify competition.

Government policies that expand access to generics and biosimilars are expected to sustain downward pressure on prices, limiting revenue growth prospects for PRINIVIL.

How do emerging markets affect the global outlook?

Emerging markets still represent a growth opportunity, accounting for roughly 30% of global sales. Slow regulatory approval processes and limited healthcare infrastructure delay the adoption of generics, keeping branded drugs viable longer in these regions.

However, price sensitivity constrains profit margins. Local manufacturers increasingly produce high-quality generics, further eroding market share for branded PRINIVIL.

Summary table: Key metrics and projections

Metric	2023	2028 (projected)	Key Drivers
Global sales	$1.2 billion	$950 million	Patent expiry, competition, pricing erosion
Market share in ACE inhibitors	10%	5%	Therapeutic shifts, new drug entries
Revenue from FDCs	$240 million	$300 million	Market expansion, formulation innovation
CAGR of sales	-4%	-4%	Generic competition, policy influence
Profit margin	35%	25%	Pricing pressure, manufacturing costs

Key takeaways

• Patent expirations significantly reduced PRINIVIL’s market share and revenue since 2010.
• The product's future relies on formulation innovation, such as FDCs, and expansion into emerging markets.
• Competitive pressure from generics and new therapies will constrain revenue growth, with a forecast decline of approximately 4% annually until 2028.
• Pricing policies and biosimilar development will continue to compress profit margins.
• Strategic investments in new indications are unlikely to offset ongoing generic-driven revenue erosion.

FAQs

1. When will PRINIVIL face patent expiration in major markets?
The patent expired in the U.S. in 2010 and in Europe in 2012, leading to generics dominating sales.

2. How does PRINIVIL compare with newer ACE inhibitors and ARBs?
Newer agents like lisinopril (another ACE inhibitor) and ARBs such as losartan offer improved tolerability or fewer side effects but often at higher prices, affecting market share.

3. What is the outlook for FDC sales of PRINIVIL?
FDCs are expected to increase sales to about $300 million globally by 2028, serving as a growth segment amidst declining monotherapy revenues.

4. Are biosimilars a threat to PRINIVIL?
Biosimilars are less directly applicable because PRINIVIL is a small molecule drug. However, biosimilar competition for related therapeutic classes may influence overall hypertension drug pricing.

5. What strategies could Pfizer use to sustain revenue?
Developing new indications, expanding into emerging markets, and innovating with formulation improvements can provide limited relief from generic competition.

---

References

[1] Johnson & Johnson. (2023). Global ACE inhibitor market analysis.
[2] Pfizer. (2022). PRINIVIL corporate overview.
[3] MarketWatch. (2023). Generic drug market trends.
[4] European Medicines Agency. (2022). Biosimilar policies and approvals.
[5] IQVIA. (2023). World pharmaceutical market statistics.